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Abstract

Author Manuscript

In this study, we investigated the therapeutic efficacy of VERU-111 in vitro and in vivo model
systems of cervical cancer. VERU-111 treatment inhibited cell proliferation and, clonogenic
potential, induce accumulation of p53 and down regulated the expression of HPV E6/E7
expression in cervical cancer cells. In addition, VERU-111 treatment also decreased the expression
of phosphorylation of Jak2 (TyR1007/1008) and STAT3 at Tyr705 and Ser727. VERU-111
treatment arrested cell cycle in the G2/M phase and modulated cell cycle regulatory proteins
(cyclin B1, p21 p34cdc2 and pcdk1). Moreover, VERU-111 treatment induced apoptosis and
modulated the expression of Bid, Bcl-xl, Survivin, Bax, Bcl2 and cleavage in PARP. In functional
assays, VERU-111 markedly reduced the tumorigenic, migratory, and invasive potential of
cervical cancer cells via modulations of MMPs. VERU-111 treatment also showed significant
(P<0.05) inhibition of orthotopic xenograft tumor growth in athymic nude mice. Taken together,
our results demonstrate the potential anti-cancer efficacy of VERU-111 in in vitro and in vivo.
VERU-111 can be explored as a potent therapeutic agent for the treatment of cervical cancer.

1.

Introduction

Author Manuscript

Cervical cancer is the world fourth largest cause of cancer-related death. The American
Cancer Society estimates that there will be 4,250 deaths, and 13,170 new cases of cervical
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cancer in the US in the year 2019 [1]. High-risk human papillomaviruses (HPV) plays a
central role in the development of 99.5% of cervical cancers [2]. HPV acts through infecting
the genital mucosa, and is integrated into the host genome, leading to the overexpression of
E6 and E7 oncoproteins, then immortalizating the host cells by disrupting p53 and pRb
functions, respectively [3]. Oncoprotein E6 binds to p53 and targets it for ubiquitin-mediated
degradation [4]. Activation of p53 further induces downstream target the gene involved in
cell cycle arrest, apoptosis, or attempts to repair the damaged DNA [5]. Cyclin-dependent
kinase (cdk) inhibitor p21cip1/waf1 and Bax mediate the cytotoxic and apoptotic effect of
p53 respectively [6]. Thus, activation of the p53 function represents a viable option for the
effective therapeutic targeting and management of cervical cancer [7]. Reactivation of p53 is
regulated either via inhibition of viral oncoproteins expression and function or in prevention
of proteasomal degradation of p53 [8]. To activate p53 in cervical cancer, several different
strategies like small molecule compounds, direct anti-E6 approaches, gamma-irradiation,
certain cytotoxic drugs, and ribozyme techniques have been adopted [4]. It has been reported
that STAT3 bind with the HPV16 LCR and regulate the abnormal E6 and E7 expression,
binding to p53, pRb and degrading HPV16 [9]. In addition, various non-coding RNAs that
modulate expression of oncogenic and tumor-suppressive genes and micro-RNAs (miRNA)
play a major role in cervical carcinogenesis development [10]. This can be a novel approach
in the treatment of cervical cancer to target these oncogenic signaling pathways and
miRNAs. Chemotherapy is currently one of the most common methods of treating advanced
metastatic cervical cancer. But the clinical application of this approach often presents serious
challenges due to the of chemoresistance and toxic side effects. A new non-toxic modality
for preventing and treating cervical cancer therefore urgently needs to be developed.

Author Manuscript
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VERU-111 was designed and synthesized based on previously reported ABI-I and ABI-II
analogues known as ABI-231 [11–13]. The novel VERU-111 (2-aryl-4-benzoyl-imidazole)
scaffold exerts its potent anti-proliferative effects by interacting with the colchicine-binding
site in tubulin. VERU-111 was found to be active on panels of melanoma, prostate and
pancreatic cancer cell lines at the nanomolar concentration and strongly suppresses
melanoma tumors in vivo [14, 15].
In this study, we evaluated the activities of VERU-111 to inhibit cervical cancer in vitro and
in vivo and investigate its underlying molecular mechanisms of action. Mechanistically, we
report that VERU-111 suppresses the expression of HPV E6 and E7 oncoproteins and
restoration of p53 levels. This which further leads to sequential reactivation of p53dependent tumor suppressor activity by downstream modulation of proteins involved in cell
proliferation, cell cycle progression and apoptosis.

Author Manuscript

2.
2.1.

Material and methods
Cell culture, growth conditions and treatment
The human cervical cancer cells (CaSki, HeLa and SiHa) that were obtained from the
American Type Culture Collection (ATCC; Manassas, VA, USA) were cytogenetically tested
and authenticated. Cervical cancer cells, CaSki were cultured in an RPMI-1640 and SiHa
and HeLa in DMEM medium, supplemented with 10% fetal bovine serum, and 1%
antibiotic and antimycotic solution (Thermo Fisher Scientific, Waltham, MA, USA).
Cancer Lett. Author manuscript; available in PMC 2021 April 21.
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Cervical cancer cells were maintained in an incubator at 37°C, 5% CO2, and a humidified
atmosphere.
2.2.

Antibodies
Antibodies against p21 (cat. # 2947), p53 (cat. # 2524), PCNA (cat. # 13110), (JAK2 (cat. #
3230), pJAK2 (cat. # 3771), STAT3 (cat. #9139), pstat3Tyr (705) (cat. # 9145), pstat3 ser
(727) (cat # 9134), (Bax (cat # 2772), Bcl2 (cat # 2872), PARP (cat. #9532), pcdk1 (cat #
9111), Cyclin B1 (cat # 4138), Bid (cat # 2002), Bim (cat # 2819), Bcl-xl (cat #2764),
Survivin (cat # 2808) and GAPDH (cat # 5174), were obtained from Cell Signaling
Technology, Inc (Danvers, MA, USA). P34cdc2 (cat# 8395), HPV E6 (cat # SC-480) and
HPV E7 (cat. # SC-698) antibodies were obtained from Santa Cruz Biotechnology, Dallas,
TX, USA.

Author Manuscript

2.3.

Cell viability and Colony forming assay
The effect of VERU-111 on cell viability was determined by the 3-(4,5-dimethylthiazole- 2yl)-2, 5-biphenyl tetrazolium bromide (MTT) assay as previously reported [16]. To
investigate the effect of VERU −111 on the clonogenic potentials of cervical cancer cells,
the colony formations assay was performed [16–18].

2.4.

Transient transfection
CaSki, cells were transiently transfected with STAT3 siRNA (100 nM), p53 siRNA (50 nM)
or control siRNA (50 nM) using Lipofectamine 2000 according to the manufacturer’s
protocol [19].

2.5.

RNA preparations and Real time PCR

Author Manuscript

RNA was extracted from cell lines and tumor xenograft by using TRIzol (Invitrogen). The
qRT-PCR was performed as previously described [16]. The primers sequences are listed in
supplementary Table. S1.
2.6.

Western blotting
Western blot analysis was performed as previously reported [16, 20].

2.7.

p53 transactivation activity

Author Manuscript

p53 transactivation assay, ELISA kit (Active Motif, Carlsbad, CA, USA) was used for the
p53 transactivation assays. The cervical cancer cells were treated with VERU-111 and
nuclear extract (Nuclear and Cytosolic Extraction Kit, Pierce, Rockford, IL, USA) was
isolated according to the manufacturer’s instructions.
2.8.

Cell migration and invasion
The scratch and migration assay was performed using a cell migration 96 well, pore size, 8
μm; Corning plate [21]. We also investigated the effect of VERU-111 on cellular motility by
an agarose bead-based cell motility assay as described earlier [21]. The invasion assay was
performed by using a cell invasion kit (BD Biocoat™ Matrigel Invasion Chambers; BD
Biosciences, San Jose, CA, USA) as describe previously [22–24].
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To further confirm the effect of VERU-111 on migration, invasion, and proliferation of
cervical cancer cells, real-time proliferation, migration and invasion assays were performed
using the xCELLigence system as described [25, 26].
2.10.

Cell cycle and apoptosis analysis

Author Manuscript

For cell cycle analysis, cells were exposed to different concentrations of VERU-111 at (0–
50 nM) for 24 h. Samples were analyzed with Accuri C6 (BD Biosciences) flow cytometer
in the FL2 channel as described [25]. Further, the Annexin V-7AAD apoptosis kit (BD
Biosciences, San Diego, CA,USA) was utilized to determine VERU-111’s ability to induce
apoptosis in cervical cancer cells as described [25]. To analyze the effect of VERU-111 on
mitochondrial membrane potential (ΔΨM), Tetramethyl rhodamine ethyl ester (TMRE)
(Invitrogen) stain method was employed as described [27].
2.11.

Orthotopic xenograft study

Author Manuscript

Six-week-old female athymic nude mice were used in accordance to protocol reviewed and
approved by the UTHSC Institutional Animal Care and Use Committee (UTHSC-IACUC).
Briefly, CaSki cells (4 × 106) were dispersed in 100 μL PBS (1X) and 100 μ L Matrigel (BD
Biosciences) and injected directly into the cervix of each mouse without any surgery. When
tumor volume reached ~200 mm3, tumor-bearing mice were randomly divided into two
groups (n=6 per group). VERU-111 (50 μg/mice) and the vehicle control (1X PBS) were
injected intratumorally three times per week for three weeks. The weight of mice as well as
tumors volume – was measured every week starting from the day when they were
administered. When tumor volume, of the control mice reached 1000 mm3, the mice were
sacrificed, and tumors were excised and used for tissue sectioning, histopathology RNA
isolations and lysate preparations.
2.12.

Immunofluorescence and immunohistochemistry analysis
Immunofluorescence and immunohistochemistry analysis were performed as describe
previously [25].

2.13.

Statistical analysis
Statistical analysis was performed with Graph Pad Prism 5 by using a Student’s t- test.

3.

Results

Author Manuscript

3.1. VERU-111 exhibits antiproliferative activity and clonogenic potential of cervical
cancer cells
HPV infections are associated with a majority of cervical cancer cases [28]. We investigated
the cytotoxic effect of VERU −111 (Figure. 1A) on cervical cancers cell lines, CaSki, HeLa,
SiHa and at various concentrations (5–80 nM). VERU-111 inhibited the growth of all three
cervical cell lines in a dose dependent manner (Figure;1Bi-iii). This finding was confirmed
by using the xCELLigence real time cell proliferation system (Figure. 1Ci–iii). For
clonogenic potential, VERU-111 significantly (p<0.05) inhibited the number of cells formed
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in all three cervical cancers cell lines compared with respective controls (Figure.1 D–F).
These findings suggest that VERU-111 treatment inhibits the proliferation and clonogenic
potential of cervical cancer cells.
3.2.

VERU-111 induces activation of p53 in cervical cancer cells

Author Manuscript

The effect of VERU-111 on HPV E6 and E7 oncogenes, p21 and p53 in CaSki and SiHa
cells was investigated by qPCR, western blot analysis and confocal microscopy. Our results
indicate a significant downregulation of both HPV16 E6 and E7 transcripts by VERU-111 in
a dose dependent manner (Figure. 2Ai–ii) by qPCR and western blot analysis (Figure. 2Ci–
ii). Moreover, the p53 dependent apoptotic pathway is are mediated through its downstream
target of p21 [29]. Therefore, we investigated the effect of VERU- 111 on p21. Interestingly,
the expression of p21 levels was significantly increased in both the mRNA (Figure 2Aiii-iv)
and the protein level (Figure. 2Ci–ii) indicating the involvement of p53 dependent apoptosis
in these cells. In addition, VERU-111 significantly induces the expression of p53 in a dose
dependent manner on mRNA levels (Figure 2Av–vi); and western blot analysis (Figure.2Ci–
ii) confirmed functional restorations in p53. Moreover, the increased p53 transactivation
following VERU-111 for 24h cervical cancer cells, confirmed that the p53 had been
functionally restored (Figure. 2Bi–ii). Further, confocal microscopic analysis again made
evident that VERU-111 led to a functional restoration of p53 and p21 as confirmed through
the increased nuclear translocation of p53 and p21 in cervical cancer cells (Figure 2Di–ii).
The above results confirmed that VERU-111 repressed both transcription and translation of
E6 and E7 oncogenes, thereby leading to the restoration of the vital tumor suppressor
pathways.

Author Manuscript

3.3. VERU-111 treatment induces the expression of 23b and miR-34a in cervical cancer
cells
Modulations of MicroRNAs are involved in cervical cancer development, progression and
metastasis. We investigated the effect of VERU-111 on the expression of miR-23b and
miR-34a by qRT-PCR in cervical cancer cells. Our results illustrated an 8- and 14-fold
induction of miR-23b expression in VERU-111 treated (20 nM) in CaSki and SiHa cells,
respectively as compared to the untreated control (Figure.2Ei–ii). MiR-34a is also
significantly upregulated by VERU-111 in dose dependent compared to untreated cells
(Figure. 2Eiii–iv). These results suggest that VERU-111 has the potential to induce the
expression of tumor suppressor miRNAs in cervical cancer cells.
3.4.

VERU-111 inhibits JAK2/ STAT3 signalling pathways

Author Manuscript

The JAK2 kinases phosphorylate STAT3 (Signal transducers and activators of transcription
3) is known to contribute to oncogenesis in cervical cancer [30]. Thus, we investigated the
effect of VERU-111 on JAK2/STAT3 and regulations of p53 in cervical cancer cells.
Interestingly, VERU-111 down regulated the expression of p-JAK2 dose dependently in
cervical cancer cell lines as determine by western blot analysis (Figure. 3A). On the other
hand, VERU-111 decreased the levels of pSTAT (Ser727) and pSTAT (Tyr705) in a dosedependent manner (Figure. 3A) as well as total STAT3 at a higher concentration (Figure.
3A). VERU-111 treatment also restored the expression of p53 levels in part due to STAT3
silencing, suggesting STAT3 inactivation as one of the mechanisms of action. VERU-111
Cancer Lett. Author manuscript; available in PMC 2021 April 21.
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resulted in lower levels of STAT3 when p53 was knocked down. This result suggests that
VERU-111 induced p53, which further caused decreases in STAT3 levels (Figure. 3B).
These results suggest that VERU-111 regulated STAT3 expression and induced p53.
3.5.

VERU-111 arrests cell cycle at G2/M phase

Author Manuscript

Excessive cell cycle progression is a major problem with cancerous cells, so drugs that can
block cell cycle progression are highly desirable. CaSki and SiHa cells were stained with
Propidium Iodide, and flow cytometer results revealed that VERU-111 arrested cell cycle
progression of CaSki (Figure. 4Ai–ii) and SiHa (Supplementary Figure. S1Ai–ii) cells at
G2/M phase in dose dependent manner in contrast to the vehicle control. Our western blot
analysis demonstrated that a decrease in cyclin B1 levels, suggests a possible late G2 or Mphase arrest in cervical cancer cells (Figure. 4Bi–ii). Since VERU-111 induced G2/M phase
arrest, we were interested into determining its effect on p34cdc2, a key regulator of G2/M
transition and its interaction with cyclin B1. Interestingly, our data illustrated substantial
dose-dependent reeducation in both p34cdc2 and phosphor- Cdk1 levels (Figure. 4Bi–ii)
confirming G2/M arrest by VERU-111. Studies have shown that p21cip1/waf1 downstream
target of p53 directly bind to PCNA and inhibit cell cycle progression [31]. VERU-111
treatment upregulated p21cip1/waf1 and downregulated PCNA levels (Fig. 3B). Thus, our
results suggest G2/M arrest and modulation of p53-mediated cell cycle regulators by
VERU-111 in cervical cancer cells.
3.6.

VERU-111 induces apoptosis in cervical cancer cells

Author Manuscript

To determine the type of cell death induced by VERU-111, Annexin V-7AAD-based flow
cytometry - (Annexin V early apoptotic cells;)-7AAD (stains dead cells) was used for
detection of the percent apoptotic or necrotic cells. VERU-111 increased the percentage of
apoptotic cells in both early and late apoptotic phases in CaSki (Figure. 4C) and SiHa
(Supplementary Figure. S1B) in a dose dependent manner indicating apoptotic cell death.
Furthermore, we investigated the effect of VERU-111 on modulations of apoptotic proteins
by western blot analysis. Our results demonstrated that VERU-111 treatment markedly
increased the protein levels of the pro-apoptotic Bid, whereas it decreased the protein levels
of anti-apoptotic Bcl-xl and Survivin in CaSki and SiHa compared with the control group
(Figure. 4Di–ii). Collectively, our results suggest that VERU-111 significantly inhibits
proliferation through apoptotic cell death in cervical cancer cells.

Author Manuscript

Several studies have reported that Bcl-2 maintained the mitochondrial integrity, while Bax
destroyed mitochondrial integrity and caused loss of mitochondrial membrane potential
(ΔΨM) [32]. The susceptibility to apoptosis, and thus, the resulting life or death of a cell
was dependent on the ratio between Bcl-2 and Bax [32]. The depolarization of
mitochondrial membrane is considered a crucial cellular event of the intrinsic apoptotic
pathway. We also determined VERU-111’s impact on the mitochondrial membrane potential
of both cervical cancer cell lines. Cervical cancer cells were treated with VERU-111 at
concentrations 25, 50 for 24 h, and we used both flow cytometer and fluorescence
microscope studies with a Tetramethylrhodamine ethyl ester (TMRE) stain to examine
mitochondrial membrane potential. Our results revealed that VERU-111 significantly
decreased the mitochondrial membrane potential of both CaSki (Figure. 4Ei–ii) and SiHa
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cells (Supplementary Figure. S1C). VERU-111 treatment modulates p53-dependent
apoptotic markers such as Bcl2 and Bax. As expected, PARP cleavage increased in a dosedependent manner in both cell lines (Figure.4Di–ii). Taken together; these results showed
that VERU-111 was able to induce apoptosis by altering the regulation of apoptotic genes,
particularly through the upregulation of Bax and downregulation of Bcl-2.
3.7. VERU-111 inhibits cell migration, invasion, and modulate MMPs expression in
cervical cancer

Author Manuscript

The effect of VERU-111 on cell migration was examined by wound healing assay at several
concentrations (2.5–5 nM) for 24 h. We found the wound gaps in the 2.5 and 5 nM
VERU-111 treated groups were significantly wider than those in the untreated group
(Figure.5A i–ii). The cell migration was further analyzed by Transwell assay corning plate.
Similar to the results of the wound healing assay, VERU-111effectively inhibited cell
migration in a dose-dependent manner (Figure. 5C i–iii). Agarose bead assay experiments
showed a similar effect (Figure. 5B i–ii). These findings were confirmed by using the
xCELLigence real time cell migration system in cervical cancer cells (Figure. 5D i–ii)
further verifying the effects on cellular motility.
Our cell invasion assays demonstrate that VERU-111 reduces the invaded cell in a dose
dependent manner in cervical cancer cells (Figure. 5E i–ii). Compared to the control group,
VERU-111 suppressed invasion by 55.3 %, 87.66% in CaSki and 52.63%, and 77.66 % in
SiHa at 2.5 and 5 nM, respectively.

Author Manuscript

Matrix metalloproteinase (MMPs) such as MMP-2 and MMP-9 have been reported to play a
critical role in cancer cell migration and invasion by facilitating the degradation of the
extracellular matrix (ECM) and basement membrane BM [33]. Interestingly, our data
illustrated that the mRNA level of MMP-2, MMP-9, UPA and uPAR were significantly (p<
0.05) reduced and those of TIMP-1 and TIMP-2 were significantly (p< 0.05) elevated at
dose dependent manner in CaSki and SiHa cervical cancer cell (Figure. 5F). These data
show that VERU-111 most likely inhibits cervical cancer cell migration, invasion and
metastasis by downregulating the levels of uPA, uPAR, MMP-2, and MMP-9 proteolytic
enzymes, and by upregulating TIMP-1 and TIMP-2.
3.8. VERU-111 inhibits cervical cancer cell-derived orthotopic xenograft tumors in
athymic nude mice

Author Manuscript

To determine an effective dose, we treated the mice with VERU-111 (50 μg/mice, three
times a week) intratumorally in orthotopic xenograft. Our results demonstrate that intratumoral administration of VERU-111 significantly inhibited CaSki cell-derived orthotopic
xenograft tumors in athymic nude mice compared to an untreated control (Figure. 6Ai–iv).
VERU-111 administration significantly (p < 0.05) reduced both tumor volume (Figure. 6Ai ii) and weight (Figure. 6Aiii) compared to control groups. During experiments, no signs of
toxicity were present as reflected by unaltered body weights compared with the control
group (Figure.6Aiv). No mortality occurred during the study period. We observed that the
mRNA expression of E6 and E7 (Figure. 6Bi–ii.) was down-regulated, and that p21 and p53
(Figure. 6Biii–iv) are upregulated in VERU-111 treated tumors. Furthermore, the mRNA
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level expression of cell cycle regulatory markers (CDK1 and cyclin B1) was significantly
reduced in VERU-111 treated orthotopic xenograft tissue (Figure. 6Ci–ii.). VERU-111
increase the expression of pro-apoptotic markers Bid and Bim (Figure. 6Di–ii) and
modulates the expression of anti-apoptotic Bax, Bcl2, and Survivin on the mRNA level in
orthotopic xenograft tissue compared with the untreated group (Figure. 6Diii–v) which
correlates with our cell culture studies. We also investigated the effect of VERU-111 on
modulation of MMPs and their inhibitors in xenograft tumors. Our qRT-PCR result
demonstrates that expression of MMP2, MMP9, uPA, and uPAR is significantly
downregulated and TIMP2, TIMP1 markedly upregulated in VERU-111 treated groups
compared to the control group (Figure. 6Ei–vi). Interestingly, the expression of miR-23b and
miR-34a was significantly restored in VERU-111 treated xenograft tumors as determined by
qRT-PCR (Figure.6Fi–ii.). We also measured PCNA, E6, E7, p21, p53, MMP-2, MMP-9,
STAT3, pSTAT3ser727, and pSTAT3tyr705 protein expression in xenograft tumor tissues by
IHC. Compared to the control, the expression of PCNA, E6, E7 MMP-2, MMP-9, STAT3,
pSTAT3ser727, and pSTAT3tyr705 significantly decreased, while the expression of p53 and
p21 markedly increased in the treatment group (Figure. 7i–ii), which correlates with the in
vitro assessment.

Discussion

Author Manuscript

In current study, we tested the anticancer activity of novel compound VERU-111 and
explored the possible associated mechanism of action in cervical cancer. During In vitro
treatment, VERU-111 significantly inhibited growth and cell proliferation in three cervical
cancer cells with slightly different IC50 values. The sensitivity of VERU-111 is different in
all three cell lines depending on several factors such as growth rate, HPV type, copy number,
and basal level of cellular tumor-suppressor protein p53. It is well documented that HPV
oncoproteins E6 and E7 are often crucial for host cell immortalization and transformation by
targeting tumor suppressor p53 and pRb [34, 35]. Therefore, it is hypothesized that the
agent, which suppresses oncogenes E6, and E7 must upregulate the expression of cellular
tumor-suppressor proteins. Our findings suggest that VERU-111 represses HPV E6 and E7
and increases expression of p53 and its effector molecules p21cip1/waf1, indicating a
possible p53-mediated apoptosis in these cells.

Author Manuscript

The degradation of p53 was found to decrease the expression of miR-23b, which leads to an
increase in expression of urokinase-type plasminogen activator (uPA), thus, inducing
migration of human cervical carcinoma [36]. Our qRT-PCR results indicated an 8- and 14fold increase in miR-23b expression in VERU-111 treated (20nM) CaSki and SiHa cells,
respectively, as compared to the untreated control. Several studies have previously reported
that miR-34a is a direct transcriptional target of p53. The binding of p53 to a consensus
triggers transactivation of the miR-34a expression-binding site present in the miR-34a
promoter region [37, 38]. MiR-34a expression is downregulated in most cervical cancer
tissues with oncogenic HPV infection by destabilizations of p53. Thus, we investigated the
effect of VERU-111 on expression of miR-34a in cervical cancer cells. VERU-111
significantly (p < 0.05) induced the expressions of miR-34a. This suggests that VERU-111
has the potential to induce the expression of tumor suppressor miRNAs in cervical cancer
cells.
Cancer Lett. Author manuscript; available in PMC 2021 April 21.
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Janus kinase 2 (JAK2), is a non-receptor tyrosine kinase involved in many signaling
pathways that modulate cell apoptosis, autophagy and proliferation [39]. The JAK2
phosphorylates STAT3, and activated STAT3 plays a major role in tumor progression by
promoting cell proliferation, angiogenesis and prevention of apoptosis induced by
chemotherapeutic agents [40]. On the other hand, previous studies have demonstrated that
the binding of activated STAT3 to the HPV16 LCR regulates the aberrant expression of E6
and E7. These further controls the cellular p53 and pRb, which leads to their degradation
during the natural history of HPV16 infection [9]. The increased level of STAT3 is also
associated with an increased expression of Bcl-xL, Survivin and mcl-1, which have shown a
strong correlation with pSTAT3 levels in cervical lesion [41]. In our results, VERU-111 not
only decreased the expression of pJAK2 at Tyr1007/1008 and STAT3 phosphorylation at
Tyr705 and Ser727 residues; it also decreased the expression of total STAT3 levels (at higher
concentrations). Interestingly, the induced expression of p53 by VERU-111 also suggests
that this agent must partly be responsible for lowering STAT3 levels. Thus, our findings
suggest that VERU-111 inhibited STAT3 levels both directly as well as indirectly, via the
restored p53 expression in CaSki cells.

Author Manuscript

Abnormal regulation of cell cycle progression is one of the hallmarks of cancer cells [42].
Our results show that VERU-111 arrests the cell cycle at the G2/M phase and modulates cell
cycle regulators such as cyclin B1, p21cip1/waf1 and p34cdc2. VERU-111 decreased
p34cdc2 and pCdk1, further leading to decreased cyclin B1- p34cdc2 complex formation, in
turn causing cell cycle arrest at the G2/M phase. Several studies have demonstrated that
p21cip1/waf1, a universal inhibitor of cdk, is known to inhibit p34cdc2 [43]. Therefore,
decreased expression of p34cdc2 could also be due to an increase in p21cip1/waf1 as caused
by VERU-111. Upon activation, p21cip1/waf1 binds to PCNA and results in growth arrest
by preventing DNA replication [44]. VERU-111 treated cervical cancer cells clearly
demonstrated a decrease in PCNA levels and an increased interaction between p21cip1/waf1
and PCNA. Therefore, we presume that p21cip1/waf1, partly due to interaction with PCNA,
may have a proapoptotic effect[45, 46].

Author Manuscript

A number of small molecules are known to cause DNA damage and activate the p53
pathway to induce growth arrest and apoptosis [47]. It has been previously reported that this
effect is due to direct activation of the proapoptotic protein Bax in p53-mediated apoptosis
[48]. Our western blot results confirm that VERU-111-induced cell death in cervical cancer
cells and was accompanied by an upregulation of Bax and downregulation of the
antiapoptotic protein Bcl2. An increased ratio of Bax: Bcl2 was found to increase the cells’
susceptibility to undergo apoptosis and activate the release of cytochrome c from
mitochondria into the cytosol [49]. Subsequently, cytochrome c cleaves procaspase-3 into
active caspase 3, which in turn leads to PARP cleavage. Our study clearly demonstrates the
restoration of p53 levels by VERU-111, resulting in the modulation of the Bax/Bcl2 ratio
and caspase-3 mediated apoptosis in cervical cancer cells.
Cervical cancer cells collectively proliferate and invade the stroma, forming groups, nests
and tubular architecture. Cell migration is a key characteristic of cancer cells. Metastasis is
the main reason for treatment failure in cancer [50]. In cervical cancer with poor prognosis,
proteolytic enzymes such as Matrix MMP-2, MMP-9 and uPA play a very important role in
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ECM and BM degradation [33]. Moreover, ECM degradation promotes cell invasion and
migration [51]. Our results demonstrate that VERU-111 not only reduced the invasion and
the migration of cervical cancer cells, but also significantly inhibited the expression of
MMP-2, MMP-9, uPA and uPAR., Interestingly, treatment of VERU-111 significantly
increased the expression of TIMP-1 and TIMP-2, which indicated that VERU-111 inhibited
the invasion and migration of cervical cancer cells through downregulation of the expression
of MMP-2, MMP-9 and uPA.

Author Manuscript

Based on the high antiproliferative activity of VERU-111 against cervical cancer cells in
vitro, we tested its effective dose against cervical cancer cell-derived orthotopic xenograft
tumors in athymic nude mice. In our in vivo findings, downregulation of HPV16 E6 and E7
oncoproteins and an increase in p53 levels in the VERU-111 treated animals were consistent
with cell culture findings. Our results demonstrate that VERU-111 has a strong and
significant in vivo antiproliferative activity against cervical cancer growth, in a p53dependent manner.
In summary, we have the shown potential anti-cancer effects of VERU-111 against cervical
cancer cells and in vivo. VERU-111 efficiently represses HPV E6 and E7 oncogenes,
resulting in sequential reactivation of p53 dependent tumor suppressor activity leading to
cervical cancer tumor growth. Our findings provide a strong basis for further exploration of
VERU-111 as a therapeutic drug against cervical cancer in monotherapy or adjuvant to
standard chemotherapeutic agents, to treat primary/ persistent/ recurrent cervical cancer
patients.
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Highlights
•

HPV E6 and HPV E7 oncoproteins play important roles in tumorigenesis and
cervical cancer progression.

•

VERU-111 concomitantly downregulates HPV E6 and E7 expression via the
activations of p53.

•

VERU-111 decreased the expression of phosphorylation of Jak2 / STAT3 and
display p53-mediated apoptosis.

•

VERU-111 exhibits potent anti-tumor activity in in vitro and in vivo
orthotopic xenograft mouse model of cervical cancer.
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Figure 1. VERU-111 inhibits the growth cervical cancer cells

Author Manuscript

A. Structure of VERU-111 B. Effect of VERU-111 on cell viability of CaSki (i), SiHa (ii)
and HeLa (iii) cells. Briefly, cells (5000) were seeded in 96-well plates and after overnight
incubation; cells were treated with the indicated concentrations of VERU-111 for 24, 48 and
72 h. Cell viability was assessed by MTT assay. The line graph represents the percentage of
viable cells compared to the untreated-treated group cells. The concentration value is the
mean ± SE of triplicate wells of each group. C. Effect of VERU-111 on cervical cancer cells
proliferation by xCELLigence Real Time Cell Analyzer (RTCA). Briefly, cervical cancer
cells (5,000 cells/well) were seeded in an E-plate (xCELLigence) following the
xCELLigence Real Time Cell Analyzer (RTCA). After 24 h, VERU-111 was added and the
experiment was allowed to run for 50 h. The Average baseline cell index for VERU- 111
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treated CaSki (i), SiHa (ii) and HeLa (iii) cells were compared to the untreated control
group. D. Effect of VERU-111 on clonogenic potential of cervical cancer cells.
Representative colony images of control and VERU-111treated CaSki (Di), SiHa (Ei) and
HeLa (Fi) cervical cancer cells. Bar graphs indicating quantification of colony formation in
CaSki (Dii), SiHa (Eii) and HeLa (Fii) cervical cancer cells. Asterisk (*) denotes the
significant value p<0.05.
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Figure 2: Effect of VERU-111 on expression of p53, miR-23b and miR-34a in cervical cancer
cells

Author Manuscript

A. Effect of VERU-111 on the expression of HPV oncogenes E6 and E7 (i-ii), p21 (iii-iv)
and p53 (v-vi) in cervical cancer cells was analyzed through real time PCR expression
analysis where GAPDH RNA was used for normalization (*p < 0.05). Data presented as
mean ± SD and are representative of three independent experiments. B. Increased level of
p53 was measured by p53 transactivation assay in CaSki and SiHa cells treated with
VERU-111 for 24h in comparison to controls. C. Effect of VERU-111 on expression of E6,
E7, p53 and p21 proteins in cervical cancer was detected by western blot analysis and
GAPDH was used as loading control. The representative data of three independent
experiments is presented. D. Expression and localization p21 (red) and p53 (green) in
cervical cancer cells treated with VERU-111 (10 nM) for 18h was determined by
immunofluorescence and confocal microscopy. Images were captured under 40x
magnification and are representative images of three independent experiments. E. Increase
in the expression of 23b and miR-34a in cervical cancer cells treated with VERU-111 for 24
h in comparison to non- treated controls. (*p < 0.05) was determined through real time PCR.
Data presented as mean ± SD and are representative of three independent experiments.
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Figure 3: Effect of VERU-111 on JAK2/ STAT3 signaling pathway

(A) Briefly, cervical cancer cells were treated with VERU-111 at indicated concentration for
24 h and subjected to western blot analysis to detect protein levels (B) CaSki cells were
transfected with control siRNA, siSTAT3 or sip53, followed by treatment with VERU-111 at
20 nM for 24 h. Cell lysates were used for western blot analysis with STAT3, p53 and
GAPDH antibodies.
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Figure 4. Effect of VERU-111 on cell cycle progression and apoptosis in cervical cancer cells
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A. VERU-111 arrests CaSki cells cycle in G2/M phase as determined by flow Cytometry.
Histogram (Ai) and table (Aii) represent the cell-cycle distribution in CaSki cells. B. Effect
of VERU-111 on protein levels of cell cycle regulatory proteins (pcdk1, p34cdc2
CyclinB1and PCNA in both CaSki (Bi), and SiHa (Bii) cells. Briefly, cervical cancer cells
were treated with the indicated concentrations of VERU-111 for 24 h; total cell lysates were
prepared and subjected to Western blot analysis. Equal loading of protein in each lane was
determined by probing the blots with GAPDH antibody. C. VERU-111 treatment induces
apoptosis in cervical cancer cells. CaSki cells were treated with the indicated concentration
of VERU-111 for 24 h and processed for apoptosis analysis using the Annexin V-7AAD
Apoptosis Kit. Representative FL3-A and FL2-A plots showing dose-dependent increase of
apoptosis in CaSki cells. D. VERU-111 treatment regulates apoptosis regulatory protein in
cervical cancer cells. Briefly, 70% confluent cervical cancer cells were treated with
VERU-111 at different concentrations for 24 h and whole cell lysates was prepared and
subjected to Western blot analysis of apoptosis regulatory proteins (Bid, Bcl-xL, Survivin,
Bax, Bcl2, and PARP cleavage) in both CaSki (Di), and SiHa (Dii). E. Effect of VERU-111
on mitochondrial membrane potential (ΔΨM) as determined by TMRE staining.
Representative fluorescence images showing dose-dependent effect of VERU-111 on TMRE
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staining in CaSki cells (Ei). Bar graph indicating dose dependent inhibition of mitochondrial
membrane potential (ΔΨM) in VERU-111 -treated CaSki cells as determined by flow
cytometry (Ei). Asterisk (*) denotes the significant value P < 0.05.
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Figure 5. Effect of VERU-111 on cell invasion, migration, and MMPs markers in cervical cancer
cells
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A, B. Effect of VERU-111 on cell motility of cervical cancer cells as determined by scratch
wound and agarose bead assays. (A) Representative images of migratory cervical cancer
cells in control and treated groups at 0, 24 h as determined by scratch wound assay. (B)
Representative images of migratory cells in control and VERU-111 treated groups at 0 and
24 h as determined by agarose bead assays. AB denotes agarose bead. C, D Effect of
VERU-111 on cell migration of cervical cancer cells as determined by Boyden chamber and
xCELLigence assays. C. Representative images (20 X original magnification) showing
inhibition of cervical cancer cells migration by Boyden chamber assay. D. Effect of
VERU-111 on real-time cell migration as determined by xCELLigence assay. Briefly,
cervical cancer cells (7× 104) were seeded in migration plate and VERU-111 treatment (2.5–
5 nM) was given after 15 h and plate was allowed to incubate at 37ºC and 5% CO2 for realtime migration assay up to 48 h. Results indicate significant decrease in migratory potential
of VERU-111 treated cervical cancer cells compared with control. E. Effect of VERU-111
on invasion of cervical cancer cells as determined by Boyden chamber. Representative
photographs (20x original magnification) of invaded cells of control and VERU-111 treated
cervical cancer cells as determined by Boyden Chamber Kit. F. Effect of VERU-111 on
expression on MMPs in cervical cancer cells as determined by qRT-PCR. Briefly, 70%
confluent cervical cancer cells were treated with VERU-111 (5–20 mM) for 24 h. RNA was
isolated and cDNA was prepared and subjected to qRT-PCR for MMPs analysis. Asterisk (*)
denotes the significant value P < 0.05.
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Figure 6. VERU-111 inhibits cervical tumor growth in xenograft mouse model
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A, Effect of VERU-111 on CaSki cells derived xenograft tumors in female athymic nude
mice. In brief, 12 mice were used in this experiment and were divided into two groups. A
total of 4× 106 CaSki cells were injected directly into the cervix of each mouse without any
surgery. VERU-111 was administered (50 μg, intra-tumorally three times per week for three
weeks) and control group mice received PBS as vehicle control. Representative mouse
picture of control and VERU-111 -treated tumor bearing mouse (i). Average tumor volume
of each group of mice at different days (ii). Bar graph representing tumor weight of each
group of mice (iii). Body weights compared with the control group (iv). B. Effect of
VERU-111 on expression of E6 (i), E7 (ii), p53 (iii), and p21 (iv) in treated or control
excised tumors as determined by qRT-PCR analysis. C. Effect of VERU-111 on mRNA
expression of cell cycle regulatory markers (i-ii). D. Pro-apoptotic markers (i-ii), antiapoptotic markers (iii-v), and E. MMPs and their inhibitors (i-vi) in orthotopic xenograft
tumor treated with VERU-111 as determined by qRT-PCR analysis. F. Effect of VERU-111
on the expression of miR-23b and miR-34a (i-ii) in orthotopic xenograft tumor treated with
VERU-111 as determined by qRT-PCR analysis. Value in graph represents mean ± SE of six
mice in each group. Asterisk (*) denotes the significant value P < 0.05.
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Figure 7. VERU-111 regulate the expression of, PCNA, E6, E7, p21, p53, MMP-2, MMP-9,
STAT3, pSTAT3ser, pSTAT3tyr in excised tumors in xenograft mouse model

Effect of VERU-111 on the expressions of, PCNA, E6, E7, p21, p53, MMP-2, MMP-9,
STAT3, STAT3ser, pSTAT3tyr in excised tumors of control (i) and VERU-111 (ii) treated
mice as determined by IHC analysis. All IHC analyses were captured at 20X magnification.
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Figure 8.

Schematic presentation of possible mechanism of VERU-111 in CxCa
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